A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
Sara Margolin(University of Copenhagen), Jonas Bergh(Karolinska Institutet), Barbro Linderholm(Karolinska University Hospital), Mats Hellström(Karolinska University Hospital), Annika Malmström(Lund University), P Karlsson, Elisabet Lidbrink(Stockholm South General Hospital), Dagny Pettersson, Henrik Lindman(Uppsala University), Lena Carlsson(University of Gothenburg)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k